2017
Age‐related macular degeneration: using morphological predictors to modify current treatment protocols
Ashraf M, Souka A, Adelman RA. Age‐related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica 2017, 96: 120-133. PMID: 29130626, DOI: 10.1111/aos.13565.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationPigment epithelial detachmentChoroidal neovascular membranePosterior vitreous detachmentNeovascular age-related macular degenerationRetinal angiomatous proliferationSubretinal fluidIntraretinal cystsVitreomacular adhesionVisual outcomeVisual acuityPrognostic indicatorMacular degenerationAnti-vascular endothelial growth factorLarger choroidal neovascular membranesWet age-related macular degenerationOlder ageCNV sizeFinal visual outcomeGood visual outcomeAnti-VEGF therapyPoor prognostic indicatorCurrent treatment protocolsEndothelial growth factorInjection frequency
2016
Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2013
Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents
Abedi G, Adelman RA, Salim S. Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars In Ophthalmology 2013, 28: 126-130. PMID: 23631423, DOI: 10.3109/08820538.2013.771195.Peer-Reviewed Original ResearchConceptsPersistent ocular hypertensionIntraocular pressureOcular hypertensionIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factor agentsChronic intraocular pressure elevationEndothelial growth factor agentsIntravitreal anti-VEGF injectionsAntivascular endothelial growth factorAnti-VEGF injectionsGrowth factor agentsIntraocular pressure elevationElevated intraocular pressureElectronic literature searchEndothelial growth factorKey search termsFactor agentsPrompt diagnosisVEGF injectionAcute elevationIntravitreal injectionIOP elevationPersistent elevationPressure elevationGlaucomatous eyes
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator